Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain

International Journal of Neuropsychopharmacology

Volumn 15, Issue 4, 2012, Pages 509-521

  Maheux, Jérôme ^a   Vuillier, Laura ^a   Mahfouz, Mylène ^a   Rouillard, Claude ^b,c   Lévesque, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Université Laval   (Canada)

Author keywords

Antipsychotic drug; in situ hybridization; noradrenalin; serotonin; striatum

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ADRENERGIC RECEPTOR; HALOPERIDOL; MDL 1193; MESSENGER RNA; NEUROLEPTIC AGENT; NUCLEAR RECEPTOR NUR77; PRAZOSIN; SEROTONIN 2A AGONIST; SEROTONIN RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADRENERGIC AGENTS; ANIMALS; BRAIN; DNA-BINDING PROTEINS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; HALOPERIDOL; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; RNA, MESSENGER; SEROTONIN AGENTS;

EID: 84862638805     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000630     Document Type: Article

References (49)

1. Andersson JL, Nomikos GG, Marcus M, Hertel P, et al. (1995). Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn-Schmiedebergs Archives of Pharmacology 352, 374-385.
2. Appel NM, Mitchell WM, Garlick RK, Glennon RA, et al. (1990). Autoradiographic characterization of ( +x)-1-(2,5-dimethoxy-4-[125I]iodophenyl)- 2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. Journal of Pharmacology & Experimental Therapeutics 255, 843-857.
3. Beaudry G, Langlois M-C, Weppe I, Rouillard C, et al. (2000). Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. Journal of Neurochemistry 75, 1694-1702.
4. Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, et al. (2009). F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist and 5-HT1A receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. European Journal of Pharmacology 620, 27-35.
5. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96. (Pubitemid 26053226)
6. Casey DE (1991). Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia Research 4, 109-120.
7. Conn PJ, Jones CK, Lindsley CW (2009). Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends in Pharmacological Sciences 30, 148-155.
8. Ethier I, Beaudry G, St-Hilaire M, Milbrandt J, et al. (2004a). The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology 29, 335-346. (Pubitemid 38175152)
9. Ethier I, Kagechika H, Shudo K, Rouillard C, et al. (2004b). Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biological Psychiatry 56, 522-526. (Pubitemid 39278251)
10. Fink-Jensen A, Ludvigsen TS, Korsgaard N (1995). The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of alpha1-adrenergic or 5HT2 receptor blockade to haloperidol. Neuroscience Letters 194, 77-80.
11. Gervais J, Soghomonian J-J, Richard D, Rouillard C (1999). Dopamine and serotonin interactions in the modulation of the expression of the immediate-early transcription factor, nerve growth factor-inducible B, in the striatum. Neuroscience 91, 1045-1054. (Pubitemid 29225635)
12. Gilbert F, Morissette M, St-Hilaire M, Paquet B, et al. (2006). Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover. Biological Psychiatry 60, 538-547. (Pubitemid 44402380)
13. Gobert A, Millan MJ (1999). Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38, 315-317. (Pubitemid 29073553)
14. Gofflot F, Chartoire N, Vasseur L, Heikkinen S, et al. (2007). Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell 131, 405-418. (Pubitemid 47576140)
15. Grenhoff J, Svensson TH (1993). Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. European Journal of Pharmacology 233, 79-84. (Pubitemid 23091746)
16. Hertel P, Fagerquist MV, Svensson TH (1999). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by a2 adrenoceptor blockade. Science 286, 105-107. (Pubitemid 29484485)
17. Humphries A, Weller J, Klein D, Baler R, et al. (2004). NGFI-B (Nur77/Nr4a1) orphan nuclear receptor in rat pinealocytes: circadian expression involves an adrenergic-cyclic AMP mechanism. Journal of Neurochemistry 91, 946-955. (Pubitemid 39507371)
18. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, et al. (2001). 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76, 1521-1531. (Pubitemid 32198256)
19. Ichikawa J, Meltzer HY (2000). The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Research 858, 252-263. (Pubitemid 30119986)
20. Invernizzi RW, Garavaglia C, Samanin R (2003). The a2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms. Neuropsychopharmacology 28, 872-879.
21. Langlois M-C, Beaudry G, Zekki H, Rouillard C, et al. (2001). Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience 106, 117-128. (Pubitemid 32831079)
22. Laprade N, Radja F, Reader TA, Soghomonian JJ (1996). Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. Journal of Neuroscience 16, 3727-3736.
23. Lévesque D, Rouillard C (2007). Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends in Neurosciences 30, 22-30. (Pubitemid 46001681)
24. Liégeois J-F, Ichikawa J, Meltzer HY (2002). 5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Research 947, 157-165.
25. Maheux J, Ethier I, Rouillard C, Lévesque D (2005). Induction patterns of transcription factors of the Nur family (Nurr1, Nur77 and Nor-1) by typical and atypical antipsychotics in the mouse brain: implication for their mechanism of action. Journal of Pharmacology & Experimental Therapeutics 313, 460-473. (Pubitemid 40411373)
26. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, et al. (2005). Combined a2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. International Journal of Neuropsychopharmacology 8, 315-327. (Pubitemid 41002487)
27. Maxwell MA, Muscat GEO (2005). The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nuclear Receptor Signaling 4, e002 Epub.
28. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (Suppl.), S106-S115.
29. Meltzer HY, Huang M (2008). In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Progress in Brain Research 172, 177-197.
30. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27, 1159-1172. (Pubitemid 37464960)
31. Merchant KM, Dorsa DM (1993). Differential induction of neurotensin and c-fos gene expression by typical vs. atypical antipsychotics. Proceedings of the National Academy of Sciences USA 90, 3447-3451. (Pubitemid 23111383)
32. Millan MJ, Dekeyne A, Gobert A (1998). Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37, 953-955.
33. Myers SA, Eriksson N, Burow R, Wang SC, et al. (2009). b-adrenergic signaling regulates NR4A nuclear receptor and metabolic gene expression in multiple tissues. Molecular and Cellular Endocrinology 309, 101-108.
34. Ohno Y, Shimizu S, Imaki J (2009). Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. Journal of Pharmacological Sciences 109, 593-599.
35. Ohno Y, Shimizu S, Imaki J, Ishihara S, et al. (2008). Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 55, 717-723.
36. Pearen MA, Myers SA, Raichur S, Ryall JG, et al. (2008). The orphan nuclear receptor, NOR-1, a target of b-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 149, 2853-2865. (Pubitemid 351724495)
37. Ponnio T, Conneely OM (2004). Nor-1 regulates hippocampal axon guidance, pyramidal cell survival, and seizure susceptibility. Molecular and Cellular Biology 24, 9070-9078. (Pubitemid 39313911)
38. Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. Journal of Pharmacology & Experimental Therapeutics 271, 1058-1066. (Pubitemid 24377799)
39. Schaffer DJ, Tunc-Ozcan E, Shukla PK, Volenec A, et al. (2010). Nuclear orphan receptor Nor-1 contributes to depressive behavior in the Wistar-Kyoto rat model of depression. Brain Research 1362, 32-39.
40. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73. (Pubitemid 26112775)
41. Serretti A, De Ronchi D, Lorenzi C, Berardi D (2004). New antipsychotics and schizophrenia: a review on efficacy and side effects. Current Medicinal Chemistry 11, 343-358. (Pubitemid 38240211)
42. Shen PJ, Gundlach AL (2000). Differential modulatory effects of a-and b-adrenoceptor agonists and antagonists on cortical immediate-early gene expression following focal cerebrocortical lesion-induced spreading depression. Brain Research. Molecular Brain Research 83, 133-144.
43. St-Hilaire M, Bourhis E, Lévesque D, Rouillard C (2006). Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77 knockout mice. European Journal of Neuroscience 24, 795-805.
44. Tremblay P-O, Gervais J, Rouillard C (1998). Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists. European Journal of Neuroscience 10, 3546-3555. (Pubitemid 29074145)
45. Wadenberg ML, Hertel P, Fernholm R, Hygge Blakeman K, et al. (2000). Enhancement of antipsychotic-like effects by combined treatment with the a1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. Journal of Neural Transmission 107, 1229-1238.
46. Wadenberg ML, Wiker C, Svensson TH (2007). Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive a2 adrenoceptor blockade: experimental evidence. International Journal of Neuropsychopharmacology 10, 191-202.
47. Werme M, Ringholm A, Olson L, Brené S (2000). Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine. Brain Research 863, 112-119. (Pubitemid 30201590)
48. Westerink BHC, Kawahara Y, De Boer P, Geels C, et al. (2001). Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. European Journal of Pharmacology 412, 127-138. (Pubitemid 32124859)
49. Zetterström RH, Williams R, Perlmann T, Olson L (1996). Cellular expression of the immediate-early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Molecular Brain Research 41, 111-120. (Pubitemid 26288151)